Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC23908 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 122 |
0.1-0.2 | 1385 |
0.2-0.3 | 5698 |
0.3-0.4 | 13206 |
0.4-0.5 | 9935 |
0.5-0.6 | 531 |
0.6-0.7 | 12 |
0.7-0.8 | 0 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC23908 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 133 |
0.1-0.2 | 806 |
0.2-0.3 | 1113 |
0.3-0.4 | 3678 |
0.4-0.5 | 3048 |
0.5-0.6 | 359 |
0.6-0.7 | 23 |
0.7-0.8 | 1 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7667 |
Intermediate Similarity |
NPD2512 |
Phase 3 |
0.6621 |
Remote Similarity |
NPD9567 |
Approved |
0.6621 |
Remote Similarity |
NPD552 |
Approved |
0.6621 |
Remote Similarity |
NPD553 |
Approved |
0.6516 |
Remote Similarity |
NPD1116 |
Approved |
0.6516 |
Remote Similarity |
NPD1113 |
Approved |
0.6424 |
Remote Similarity |
NPD1588 |
Clinical (unspecified phase) |
0.634 |
Remote Similarity |
NPD684 |
Approved |
0.634 |
Remote Similarity |
NPD686 |
Approved |
0.6328 |
Remote Similarity |
NPD6891 |
Phase 2 |
0.6258 |
Remote Similarity |
NPD5580 |
Discontinued |
0.6258 |
Remote Similarity |
NPD3170 |
Approved |
0.6242 |
Remote Similarity |
NPD6414 |
Clinical (unspecified phase) |
0.6242 |
Remote Similarity |
NPD685 |
Approved |
0.6185 |
Remote Similarity |
NPD3948 |
Discontinued |
0.6184 |
Remote Similarity |
NPD3502 |
Discovery |
0.6154 |
Remote Similarity |
NPD1109 |
Approved |
0.6154 |
Remote Similarity |
NPD1110 |
Approved |
0.6133 |
Remote Similarity |
NPD6659 |
Phase 2 |
0.6084 |
Remote Similarity |
NPD2672 |
Discontinued |
0.6074 |
Remote Similarity |
NPD2737 |
Clinical (unspecified phase) |
0.6014 |
Remote Similarity |
NPD1246 |
Approved |
0.6 |
Remote Similarity |
NPD6384 |
Phase 2 |
0.6 |
Remote Similarity |
NPD6383 |
Clinical (unspecified phase) |
0.5987 |
Remote Similarity |
NPD2670 |
Approved |
0.5986 |
Remote Similarity |
NPD1279 |
Clinical (unspecified phase) |
0.5957 |
Remote Similarity |
NPD2181 |
Clinical (unspecified phase) |
0.5949 |
Remote Similarity |
NPD1626 |
Approved |
0.5918 |
Remote Similarity |
NPD1245 |
Approved |
0.5906 |
Remote Similarity |
NPD518 |
Clinical (unspecified phase) |
0.5893 |
Remote Similarity |
NPD2836 |
Approved |
0.5886 |
Remote Similarity |
NPD1194 |
Discontinued |
0.5871 |
Remote Similarity |
NPD9471 |
Clinical (unspecified phase) |
0.5867 |
Remote Similarity |
NPD1877 |
Discontinued |
0.5854 |
Remote Similarity |
NPD1801 |
Approved |
0.5854 |
Remote Similarity |
NPD1340 |
Discontinued |
0.5854 |
Remote Similarity |
NPD1802 |
Approved |
0.5818 |
Remote Similarity |
NPD7528 |
Approved |
0.5809 |
Remote Similarity |
NPD1238 |
Approved |
0.5804 |
Remote Similarity |
NPD9508 |
Approved |
0.5802 |
Remote Similarity |
NPD1625 |
Approved |
0.5789 |
Remote Similarity |
NPD1574 |
Approved |
0.5782 |
Remote Similarity |
NPD2347 |
Approved |
0.5772 |
Remote Similarity |
NPD9272 |
Approved |
0.5764 |
Remote Similarity |
NPD5277 |
Phase 2 |
0.5733 |
Remote Similarity |
NPD9692 |
Approved |
0.5733 |
Remote Similarity |
NPD9693 |
Approved |
0.5724 |
Remote Similarity |
NPD661 |
Approved |
0.5724 |
Remote Similarity |
NPD657 |
Approved |
0.5724 |
Remote Similarity |
NPD655 |
Approved |
0.5724 |
Remote Similarity |
NPD1280 |
Clinical (unspecified phase) |
0.5724 |
Remote Similarity |
NPD660 |
Approved |
0.5714 |
Remote Similarity |
NPD2034 |
Discontinued |
0.5714 |
Remote Similarity |
NPD701 |
Approved |
0.5714 |
Remote Similarity |
NPD698 |
Approved |
0.5704 |
Remote Similarity |
NPD2182 |
Approved |
0.5686 |
Remote Similarity |
NPD2199 |
Approved |
0.5686 |
Remote Similarity |
NPD2198 |
Approved |
0.5677 |
Remote Similarity |
NPD659 |
Approved |
0.5677 |
Remote Similarity |
NPD662 |
Approved |
0.5677 |
Remote Similarity |
NPD658 |
Approved |
0.5677 |
Remote Similarity |
NPD663 |
Approved |
0.5677 |
Remote Similarity |
NPD656 |
Approved |
0.5658 |
Remote Similarity |
NPD4232 |
Approved |
0.5657 |
Remote Similarity |
NPD3861 |
Approved |
0.5657 |
Remote Similarity |
NPD3862 |
Approved |
0.565 |
Remote Similarity |
NPD4679 |
Discontinued |
0.5647 |
Remote Similarity |
NPD1092 |
Approved |
0.5647 |
Remote Similarity |
NPD1093 |
Approved |
0.5647 |
Remote Similarity |
NPD3684 |
Discontinued |
0.5644 |
Remote Similarity |
NPD1189 |
Approved |
0.5643 |
Remote Similarity |
NPD164 |
Approved |
0.564 |
Remote Similarity |
NPD3388 |
Phase 1 |
0.5629 |
Remote Similarity |
NPD4888 |
Discontinued |
0.5621 |
Remote Similarity |
NPD182 |
Clinical (unspecified phase) |
0.5617 |
Remote Similarity |
NPD7137 |
Phase 2 |
0.5611 |
Remote Similarity |
NPD3449 |
Discontinued |
0.56
|
Remote Similarity |
NPD446 |
Clinical (unspecified phase) |